• Iptacopan (LNP023): Selective Factor B Inhibition for Comple

  2026-07-07

  Iptacopan (LNP023) is a potent, selective oral inhibitor of complement factor B that blocks alternative pathway C3bBb formation. Clinical and preclinical results show rapid and durable control of complement-mediated hemolysis, with high selectivity and efficacy in PNH and glomerulopathies. This dossier details Iptacopan's mechanism, validated benchmarks, and integration into complement activation research.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-07-06

  This study rigorously demonstrates sex-specific responses in the development of angiotensin II-induced hypertension in conscious mice, with male mice exhibiting a markedly greater hypertensive response compared to females. The findings offer mechanistic insight into the roles of sex hormones in blood pressure regulation and highlight important considerations for cardiovascular disease modeling.

• Azilsartan Medoxomil Monopotassium: Network Meta-Analysis in

  2026-07-06

  A recent network meta-analysis systematically compared the antihypertensive efficacy of azilsartan medoxomil (TAK 491) with other first-line agents in mild-to-moderate hypertension. The study demonstrates that azilsartan medoxomil, particularly at 80 mg, provides superior blood pressure reduction, setting a new benchmark for essential hypertension treatment research.

• Paroxetine Mesylate (C8698): Reliable SSRI for Cell Assays

  2026-07-05

  This article delivers a scenario-driven, evidence-based guide for biomedical researchers and lab technicians seeking robust, reproducible results in cell viability, proliferation, and cytotoxicity assays using Paroxetine Mesylate (SKU C8698). Drawing on validated protocol parameters and comparative analysis, it demonstrates how this selective serotonin reuptake inhibitor addresses key pain points, ensuring data quality and workflow efficiency.

• Acridine Orange hydrochloride: Technical Guide for Nucleic A

  2026-07-04

  Acridine Orange hydrochloride enables reliable differential staining of DNA and RNA in situ, supporting workflows like cell cycle analysis, apoptosis detection, and flow cytofluorometric nucleic acid staining. Its dual-fluorescence properties and membrane permeability make it suited for rapid, sensitive cytochemical assays. Avoid in applications requiring long-term solution storage or unsupported mechanistic interpretation.

• BIRB 796 (Doramapimod): Precision Inhibition in Inflammation

  2026-07-03

  BIRB 796 (Doramapimod) sets a new benchmark for selective p38α MAPK inhibition, enabling researchers to dissect inflammatory and apoptotic pathways with unprecedented clarity. Its dual-action mechanism and robust performance in both cellular and animal models provide workflow advantages that surpass conventional inhibitors.

• Angiotensin III (human, mouse): Mechanistic Insights for Pre

  2026-07-03

  Explore the unique mechanistic and structural properties of Angiotensin III (human, mouse) as a key RAAS peptide. This article delivers advanced scientific context and practical assay guidance, highlighting new cross-domain findings in viral receptor interactions.

• Cabazitaxel (XRP6258): Protocol Best Practices for Resistant

  2026-07-02

  Cabazitaxel addresses the challenge of modeling taxane-resistant and P-glycoprotein-expressing cancer cell lines where standard taxanes lose efficacy. It is specifically suited for DMSO or ethanol-based in vitro and in vivo workflows and should not be used in water-based assays or for long-term solution storage.

• QX77 (SKU BA3596): Reliable Chaperone-Mediated Autophagy Mod

  2026-07-02

  QX77 (SKU BA3596) stands out as a rigorously validated molecular chaperone activator for chaperone-mediated autophagy (CMA) research, offering reproducible results for cell viability, proliferation, and stem cell biology assays. This article explores real-world experimental challenges and demonstrates, through scenario-driven analysis, how QX77 provides data-backed solutions and practical workflow advantages.

• RNASEH1-AS1: Prognostic lncRNA and Target in Hepatocellular

  2026-07-01

  This study identifies the long non-coding RNA RNASEH1-AS1 as a robust prognostic and diagnostic biomarker in hepatocellular carcinoma (HCC), revealing its mechanistic involvement in tumor progression and immune microenvironment modulation. The research integrates transcriptomic analysis, risk modeling, and experimental validation to support RNASEH1-AS1 as a potential therapeutic target.

• Phosphatase Inhibitor Cocktail 1: Precision Control in Phosp

  2026-07-01

  Explore how Phosphatase Inhibitor Cocktail 1 (100X in DMSO) enables unparalleled protein phosphorylation preservation for advanced signaling studies. This article uniquely bridges molecular mechanism with assay optimization for phosphoproteomic analysis.

• MRT68921 ULK1 Kinase Inhibitor: Precision Autophagy Blockade

  2026-06-30

  MRT68921 empowers researchers with nanomolar precision for dissecting autophagy signaling, offering a potent, selective tool to block ULK1/2 activity and interrogate the initiation phase of autophagy. Its compatibility with quantitative assays, like ATG13 phosphorylation and LC3 flux measurement, enables high-confidence mechanistic studies and workflow reproducibility.

• USP36-Snail1 Axis Drives Ribosome Biogenesis in Cancer Stres

  2026-06-30

  This study uncovers how USP36 stabilizes nucleolar Snail1, enabling cancer cells to sustain ribosome biogenesis and survive ribotoxic stress. The work identifies the JNK-USP36-Snail1 signaling cascade as a key resistance mechanism in solid tumors, suggesting new targets for enhancing ribosome inhibition-based therapies.

• CD163+ Macrophage Activation Drives Granulosa Cell Apoptosis

  2026-06-29

  This study demonstrates that increased CD163+ macrophage activation and high CD163 expression directly promote granulosa cell apoptosis in polycystic ovary syndrome (PCOS). By using a DHEA-induced mouse model and patient samples, the research delineates a mechanistic link between inflammatory macrophages and ovarian dysfunction, offering new insights for therapeutic intervention.

• AP20187: Precision Tools for Protein Dimerization in Neuroim

  2026-06-29

  Discover how AP20187, a leading chemical inducer of dimerization, empowers advanced neuroimmune and pain pathway studies. Explore protocol optimization, mechanistic insights, and practical assay guidance distinct from prior reviews.

449 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page